The Cartelization of American Healthcare: How Middlemen Broke the System
I learned how broken this is the hard way. A round of routine bloodwork, the same tests, the same vials, cost me nearly double simply because I was drawn at a rural hospital instead of a larger in-network facility down the road. Nothing about the test changed. The needle was the same, the lab work was the same, only the invoice was different. That is not a pricing structure, that is a toll booth, and it is one more reason I started asking who actually benefits when healthcare gets this complicated.
The traditional doctor-patient relationship has been systematically dismantled and replaced by a corporate-driven landscape dominated by massive hospital networks, private equity buyouts, and insurance oligopolies. We are no longer dealing with a localized healthcare market; we are dealing with a captured medical cartel. Through unchecked consolidation and the exploitation of administrative loopholes, the American healthcare system has transitioned from a service designed to heal into an extraction mechanism designed to funnel middle-class wealth into corporate dividends.
Recently, while going in to make a payment to a local hospital, I asked them why the price seemed so high compared to when I go to another hospital to get bloodwork done. Their response to me was that they are classified as a rural hospital and they charge my insurance double—and in turn, I have to pay double until my deductible is met. Is this listed anywhere? No. Do they participate in upfront pricing? No. I am stuck with double the bill simply because of the location of the hospital being closer to my house.
The Ghost of Direct Pricing
There was an era when medical care functioned on a transparent, direct fee-for-service structure with manageable deductibles. Regional competition among smaller practices and local insurers kept costs somewhat tethered to reality. You paid for a service, the doctor provided it, and catastrophic insurance protected you from bankruptcy.
That market choice has vanished. Heavy regulatory compliance and the sheer cost of navigating modern billing codes forced independent physicians to sell their practices to massive hospital networks. This consolidation killed regional competition, placing pricing power squarely in the hands of a few mega-insurers and unified hospital conglomerates who negotiated entirely behind closed doors.
The ACA Compromise: Mandating Corporate Profit
The turning point in modern medical consolidation was the Patient Protection and Affordable Care Act (ACA). Sold as a lifeline to the uninsured, the legislation ultimately served as a legally mandated wealth transfer to private insurers. The ACA legally forced the middle class to purchase defective, high-deductible products from a private insurance oligopoly.
During legislative negotiations, industry lobbyists successfully stripped the public option—a Medicare-style fallback framework—from the final bill. The removal of the public option eliminated the only mechanism that could have forced private insurers to compete on price, effectively creating a captive market where consumers are mandated to buy in, but insurers face no baseline federal competition to keep their premiums honest.
The financial results for these corporations are staggering. UnitedHealth Group reported 2024 revenues of $400.3 billion, generating $24.2 billion in cash flows from operations. The company projects its 2025 revenue to climb even higher, reaching between $450 billion and $455 billion.
The Middleman Tax: Administrative Bloat and PBMs
The true cost drivers in American healthcare are not the doctors or the nurses, but the bureaucratic swarm of middlemen standing between the patient and the provider. Between 1975 and 2010, the number of healthcare administrators increased by 3,200%, vastly outpacing physician growth, which only increased by 150% during the same period. We are paying a massive premium to employ an army of billing coders, compliance officers, and executives whose primary function is to deny coverage or maximize billing extraction.
The most egregious examples of this parasitic drain are Pharmacy Benefit Managers (PBMs). Entities like CVS Caremark, Express Scripts, and OptumRx control the vast majority of the prescription drug supply chain. Operating as shadowy middlemen, PBMs dictate what drugs are covered, extort manufacturers for placement on formularies, and pocket massive rebates while forcing the patient to pay the inflated sticker price at the pharmacy counter.
Simultaneously, the hospitals themselves are merging into unchecked regional monopolies. In early 2025, Sanford Health merged with Marshfield Clinic Health System to create a 56-hospital integrated system. Shortly after, Northwell Health and Nuvance Health completed a merger in May 2025, forming a combined health system with 28 hospitals and a staggering $22.6 billion operating budget.
The Pricing Black Box and International Disparity
Because of this consolidation and administrative bloat, the American medical system operates as a financial black box. It is the only industry where a consumer cannot get a straight answer on the cost of a service until weeks after the procedure is completed.
To understand the absurdity of our pricing, we must compare it to international baselines. Premium screening programs in the United States charge between $2,499 and $3,999 for full-body MRI scans.
The Missing Middle: Too Rich for Aid, Too Poor for Care
The current system protects the poorest through Medicaid and serves the wealthiest who can afford premium concierge care out-of-pocket. The middle class is left to shoulder the entire financial burden.
Working families are paying exorbitant monthly premiums that subsidize the rest of the system, yet their deductibles are so high that they are functionally uninsured for everyday illnesses. This deferred care acts as a hidden tax. Middle-class Americans avoid the doctor because they cannot afford an $8,000 deductible, meaning they are paying thousands of dollars a year for a product they actively hope they never have to use.
When the uninsured and underinsured inevitably delay essential preventive care, minor issues escalate into severe complications. They are eventually forced to use the Emergency Room as a primary care physician, driving up operational costs that are ultimately transferred right back to the taxpayer and the middle-class premium payer.
The Public Option as an Anti-Monopoly Tool
In the last couple of years, this topic in particular has dropped off the radar of many politicians. As inflation hits our wallets more than ever, it is important to take a look at the amount of money being poured into a few select companies at the cost of our health. The status quo is a system where working Americans are forced to fund the record profits of a corporate cartel simply to survive.
If we are going to break the medical cartel, we must stop viewing the public option as a traditional welfare entitlement and recognize it as a necessary anti-monopoly tool. A robust public option is the crowbar needed to smash the insurance oligopoly, reintroduce baseline price competition into a captured market, and force corporate conglomerates to justify their administrative bloat. Rather than a government takeover, a public option acts as a transparent, federal benchmark that private insurers must actively compete against, stripping them of their captive market.
We are beginning to see cracks in the cartel's armor, but regulatory patchwork is not enough. Following a major 2024 lawsuit against the three largest Pharmacy Benefit Managers for artificially inflating drug prices, the Federal Trade Commission (FTC) recently secured landmark 2026 antitrust settlements with massive middlemen like Express Scripts and Caremark to force business practice changes and increase transparency. Even more recently, in October 2026, the FTC had to issue warning letters to 24 of the nation's largest healthcare organizations over their ongoing failure to provide transparent pricing to patients.
These enforcement actions prove the severity of the crisis, but true systemic reform requires permanent, structural change. It requires reclaiming price transparency as an absolute legal right, aggressively breaking up regional hospital monopolies, completely cutting out the parasitic PBM middlemen, and giving the American people the ultimate say over their own health and financial stability.
Key Takeaways
- Pharmacy benefit managers sit between patients and drugmakers, adding a middleman cost that shows up in what we pay.
- Opaque pricing hides who profits, and the missing middle earns too much for aid but too little to absorb the cost of care.
- A public option and real antitrust enforcement are presented as tools to restore competition.
This article is an opinion-based editorial. It reflects the analysis and views of the author, G. Moraga, and does not constitute independent news reporting.
If you enjoyed this article, you may also like: The Prescription Shadow Market
Don’t forget to visit us on Facebook and YouTube.
Sources & Data References:
MRI International Cost Comparison: Data aggregated from the International Federation of Health Plans (IFHP) comparative price reports and the Peterson-KFF Health System Tracker. Premium US scan pricing reflects typical out-of-pocket costs for elective, full-body preventative imaging facilities (e.g., Prenuvo).
UnitedHealth Group Financials: UnitedHealth Group Full Year 2024 Earnings Release and 2025 Financial Outlook, published January 2025.
Administrator vs. Physician Growth (1975–2010): Data tracked by the Bureau of Labor Statistics and the National Center for Health Statistics, frequently cited in healthcare economic analyses regarding bureaucratic bloat.
Hospital Network Mergers: Becker's Hospital Review and joint corporate press releases (2024–2025) detailing the finalized combinations of Sanford Health with Marshfield Clinic, and Northwell Health with Nuvance Health.
FTC PBM Lawsuits and Settlements: Federal Trade Commission (FTC) legal filings and press releases detailing the September 2024 antitrust lawsuit against the "Big Three" Pharmacy Benefit Managers (Caremark Rx, Express Scripts, and OptumRx), along with the subsequent 2026 settlement agreements secured to force business practice changes.
FTC Price Transparency Warning Letters: October 2026 industry reporting (referenced in publications like Healthcare Dive and Fierce Healthcare) covering the FTC's formal warning letters sent to 24 of the nation's largest healthcare services companies regarding their failure to provide timely and complete pricing information to patients.
